Trinity Biotech (TRIB) Competitors $1.30 -0.02 (-1.52%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRIB vs. RLYB, ANEB, CLNN, CERO, OSTX, LUMO, RAPT, NXTC, CARM, and DYAIShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Rallybio (RLYB), Anebulo Pharmaceuticals (ANEB), Clene (CLNN), CERo Therapeutics (CERO), OS Therapies (OSTX), Lumos Pharma (LUMO), RAPT Therapeutics (RAPT), NextCure (NXTC), Carisma Therapeutics (CARM), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Rallybio Anebulo Pharmaceuticals Clene CERo Therapeutics OS Therapies Lumos Pharma RAPT Therapeutics NextCure Carisma Therapeutics Dyadic International Trinity Biotech (NASDAQ:TRIB) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends. Which has more volatility & risk, TRIB or RLYB? Trinity Biotech has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.67, suggesting that its stock price is 267% less volatile than the S&P 500. Which has preferable earnings and valuation, TRIB or RLYB? Trinity Biotech has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$56.83M0.17-$24.02M-$2.26-0.58RallybioN/AN/A-$74.56M-$1.60-0.62 Is TRIB or RLYB more profitable? Rallybio has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets Trinity Biotech-34.39% N/A -21.37% Rallybio N/A -77.39%-69.33% Do institutionals and insiders hold more shares of TRIB or RLYB? 79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 7.4% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in TRIB or RLYB? Trinity Biotech received 296 more outperform votes than Rallybio when rated by MarketBeat users. However, 76.47% of users gave Rallybio an outperform vote while only 72.04% of users gave Trinity Biotech an outperform vote. CompanyUnderperformOutperformTrinity BiotechOutperform Votes33572.04% Underperform Votes13027.96% RallybioOutperform Votes3976.47% Underperform Votes1223.53% Do analysts recommend TRIB or RLYB? Rallybio has a consensus target price of $9.75, suggesting a potential upside of 880.79%. Given Rallybio's stronger consensus rating and higher probable upside, analysts plainly believe Rallybio is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to TRIB or RLYB? In the previous week, Trinity Biotech had 9 more articles in the media than Rallybio. MarketBeat recorded 9 mentions for Trinity Biotech and 0 mentions for Rallybio. Trinity Biotech's average media sentiment score of 0.73 beat Rallybio's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media. Company Overall Sentiment Trinity Biotech Positive Rallybio Neutral SummaryTrinity Biotech beats Rallybio on 10 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.91M$2.53B$5.04B$8.82BDividend YieldN/A0.76%5.17%4.07%P/E Ratio-0.584.96122.4217.58Price / Sales0.1730.911,179.2973.96Price / CashN/A16.3433.5632.51Price / Book-0.413.004.694.68Net Income-$24.02M$29.98M$118.98M$225.87M7 Day Performance-16.13%-4.55%-2.45%-2.03%1 Month Performance-23.98%-11.18%-4.03%0.07%1 Year Performance-33.50%-14.89%29.80%24.55% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech1.8087 of 5 stars$1.30-1.5%N/A-33.5%$10.06M$56.83M-0.58480Gap DownRLYBRallybio2.5309 of 5 stars$0.99+3.1%$9.75+880.8%-59.4%$39.85MN/A0.0040ANEBAnebulo Pharmaceuticals2.5011 of 5 stars$1.52flat$8.00+426.3%-30.9%$39.42MN/A-5.074Analyst ForecastShort Interest ↓News CoverageGap UpCLNNClene3.1551 of 5 stars$4.09-12.2%$71.33+1,644.1%-56.6%$38.96M$650,000.000.00100Analyst RevisionHigh Trading VolumeCEROCERo TherapeuticsN/A$0.25-3.9%N/AN/A$38.79MN/A0.008Gap DownOSTXOS TherapiesN/A$1.74-1.7%N/AN/A$37.59MN/A0.00N/AHigh Trading VolumeLUMOLumos Pharma3.2102 of 5 stars$4.32-0.2%$8.63+99.7%+41.2%$37.45M$2.05M0.0030RAPTRAPT Therapeutics4.5981 of 5 stars$1.07flat$9.50+787.9%-92.3%$37.40M$1.53M0.0080NXTCNextCure4.3842 of 5 stars$1.30-0.8%$4.00+207.7%+4.8%$36.69MN/A0.0090CARMCarisma Therapeutics3.317 of 5 stars$0.86flat$7.00+711.7%-64.7%$36.20M$14.92M0.0020DYAIDyadic International2.513 of 5 stars$1.49+22.1%$6.00+302.7%-17.7%$36.10M$2.90M0.007Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Rallybio Competitors Anebulo Pharmaceuticals Competitors Clene Competitors CERo Therapeutics Competitors OS Therapies Competitors Lumos Pharma Competitors RAPT Therapeutics Competitors NextCure Competitors Carisma Therapeutics Competitors Dyadic International Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRIB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRIB Stock Alerts